Jill M. Jene, PhD

Chief Business Officer

Dr. Jill M. Jene is NKGen Biotech’s Chief Business Officer. Dr. Jene has over 20 years of business development expertise in the life sciences industry with a deal sheet totaling over $6B in closed transactions. Prior to joining NKGen, Dr. Jene was Vice President and Head of Corporate Development, Strategy, Portfolio Planning and Alliance Management at Adamas Pharmaceuticals where she successfully led the creation and implementation of the corporate strategic plan while building out the BD opportunity process and deals until Supernus acquired Adamas for a value over $850M.

Before joining Adamas, Dr. Jene was Vice President of Business Development at PDL Biopharma where she built out the BD function and deal pipeline resulting in over $500M of value to investors through a formal dissolution process. Prior to PDL, Dr. Jene was with twoXAR as Senior Vice President of Business Development where she revamped the BD process leading to an increase in the number of key pipeline opportunities and successful deal negotiations including collaborations, spinouts, and licensing.

Prior to twoXAR, Dr. Jene was VP of Business Development at Depomed leading the team to numerous successful M&A transactions, including 4 commercial franchises, along with several profitable licensing agreements closing over 20 transactions totaling over $750 Million. Prior to joining Depomed, Dr. Jene held positions of increasing responsibilities in business and corporate development at Cell Genesys, 3M Pharmaceutical Division and Baxter International establishing a history for closing transactions including acquisitions and divestitures.

In addition to Dr. Jene’s role as CBO at NKGen, she is currently serving as a Director of the Board for Lipocine, Inc. (NASDAQ: LPCN) a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system disorders with high unmet medical needs using their proprietary delivery technology.

Dr. Jene obtained a BS degree in chemistry from Bradley University and holds both a PhD and MS in chemistry from Northwestern University, and an MBA in strategic management from DePaul University.